Cargando…
Tocilizumab administration in a refractory case of COVID-19
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264941/ https://www.ncbi.nlm.nih.gov/pubmed/32502524 http://dx.doi.org/10.1016/j.ijantimicag.2020.106043 |
| _version_ | 1783541035601756160 |
|---|---|
| author | Dastan, Farzaneh Nadji, Seyed Alireza Saffaei, Ali Tabarsi, Payam |
| author_facet | Dastan, Farzaneh Nadji, Seyed Alireza Saffaei, Ali Tabarsi, Payam |
| author_sort | Dastan, Farzaneh |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7264941 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. and International Society of Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72649412020-06-02 Tocilizumab administration in a refractory case of COVID-19 Dastan, Farzaneh Nadji, Seyed Alireza Saffaei, Ali Tabarsi, Payam Int J Antimicrob Agents Letter to the Editor Elsevier B.V. and International Society of Chemotherapy. 2020-08 2020-06-02 /pmc/articles/PMC7264941/ /pubmed/32502524 http://dx.doi.org/10.1016/j.ijantimicag.2020.106043 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Dastan, Farzaneh Nadji, Seyed Alireza Saffaei, Ali Tabarsi, Payam Tocilizumab administration in a refractory case of COVID-19 |
| title | Tocilizumab administration in a refractory case of COVID-19 |
| title_full | Tocilizumab administration in a refractory case of COVID-19 |
| title_fullStr | Tocilizumab administration in a refractory case of COVID-19 |
| title_full_unstemmed | Tocilizumab administration in a refractory case of COVID-19 |
| title_short | Tocilizumab administration in a refractory case of COVID-19 |
| title_sort | tocilizumab administration in a refractory case of covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264941/ https://www.ncbi.nlm.nih.gov/pubmed/32502524 http://dx.doi.org/10.1016/j.ijantimicag.2020.106043 |
| work_keys_str_mv | AT dastanfarzaneh tocilizumabadministrationinarefractorycaseofcovid19 AT nadjiseyedalireza tocilizumabadministrationinarefractorycaseofcovid19 AT saffaeiali tocilizumabadministrationinarefractorycaseofcovid19 AT tabarsipayam tocilizumabadministrationinarefractorycaseofcovid19 |